What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?

What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?

What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Nir Peled, MD, PhD, FCCP

Professor Nir Peled, MD, PhD, FCCP

Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel